State-of-the-Art — mRNA Circulating Tumor Cells Screening

Early detection of around 0.2 cm CTCs Tumor Cells, 93-97% in accuracy, sensitivity and specificity.

Please contact 3168-8188, Whatsapp 6218-8534 or Facebook Inbox for more detail.

mRNA Circulating Tumor Cells
Early Screening

Mechanism of angiogenesis is induced when the tumor continuing to divide and proliferate. Tumor cells will fall off from the new blood vessels into the blood circulation and forming as circulating tumor cells (CTCs). Detect around 0.2 cm Tumor cells, 93-97% in accuracy, sensitivity and specificity.

Click：Man’s 9 items CTCs Early Screening

Click：Woman’s 9 items CTCs Early Screening

mRNA Circulating Tumor Cells
Specified Screening
mRNA Circulating Tumor Cells Specified Screening can analyse 30-32 mRNA molecular marker detailedly and access the efficacy of ongoing treatment, postoperative and prognostic tracking in order to investigate a more suitable treatment for the patient.

Click：Lung Cancer CTCs Specified Screening

Click：Liver Cancer CTCs Specified Screening

Click: Liver Cancer CTCs Specified Screening

Click：Pancreatic Cancer CTCs Specified Screening

Click：Colorectal Cancer CTCs Specified Screening

Click：Head and Neck Cancers CTCs Specified Screening

Click：Nasopharyngeal Carcinoma CTCs Specified Screening

Click：Breast Cancer CTCs Specified Screening

Click：Cervical Cancer CTCs Specified Screening

Click：Prostate Cancer CTCs Specified Screening

What is mRNA Circulating Tumor Cells?

Mechanism of angiogenesis is induced when the tumor continuing to divide and proliferate. Tumor cells will fall off from the new blood vessels into the blood circulation and forming as circulating tumor cells (CTCs).

Why CTCs can detect Tumor?

Per gram of malignant tumor has about 1 million tumor cells can be released into the blood. mRNA dynamic gene technology can detect the number of CTCs; therefore, it could screen out and detect the ultra-early stage of Tumor (0.2 cm or above) by investigating CTCs

Why should I do the mRNA test?

mRNA dynamic gene technology is up to 93-97% of accuracy, sensitivity and specificity by using non-invasive and safety technology.

mRNA Circulating Tumor Cells Early Screening

Early Screening

Detect Tumor size even around 0.2cm

Screening common Tumor in Hong Kong

Including：Lung, Liver, Stomach, Pancreatic, Colorectal, Head and Neck, Nasopharyngeal Carcinoma, Breast, Prostate(Male), Cervical(Female)

High in accuracy, sensitivity and specificity

Accuracy, sensitivity and specificity are up to 93-97%

High Safety

Small amount blood requirement, minimal invasive, high safety and no radiation